U.S. FDA Clears Japan’s Astellas To Resume Death-Halted Anemia Trial
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA says Japan's Astellas Pharma and its biotech partner FibroGen may resume Phase II trials halted when a participant died. The trials of the YM 311 drug for treating anemia in pre-dialysis patients with chronic kidney disease were stopped last May. Astellas has considered the drug one of its three priority drugs in development. The trial participant who died was aged 76 and found to be taking 10 other medicines. (Click here for more